Cargando…

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease

Crizanlizumab is an anti–P-selectin monoclonal antibody indicated to reduce the frequency/prevent recurrence of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) aged ≥16 years. This analysis of an ongoing phase 2, nonrandomized, open-label study reports the pharmacokinetics (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanter, Julie, Brown, R. Clark, Norris, Cynthia, Nair, Santosh M., Kutlar, Abdullah, Manwani, Deepa, Shah, Nirmish, Tanaka, Chiaki, Bodla, Shankaranand, Sanchez-Olle, Gessami, Albers, Urs, Liles, Darla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027508/ https://www.ncbi.nlm.nih.gov/pubmed/36355805 http://dx.doi.org/10.1182/bloodadvances.2022008209

Ejemplares similares

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study
por: Heeney, Matthew M., et al.
Publicado: (2022)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
por: Kanter, J, et al.
Publicado: (2022)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

GRNDaD: big data and sickle cell disease
por: Lanzkron, Sophie, et al.
Publicado: (2022)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
por: Adamkiewicz, Thomas V., et al.
Publicado: (2023)

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
por: Dhar, Arushi, et al.
Publicado: (2021)

Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2021)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023)

Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests
por: Olaniyan, Halimat S., et al.
Publicado: (2023)

Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial
por: Namazzi, Ruth, et al.
Publicado: (2023)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

Development of a Severity Classification System for Sickle Cell Disease
por: Shah, Nirmish, et al.
Publicado: (2020)

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
por: Burke, G. A. Amos, et al.
Publicado: (2022)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Iron Overload in Sickle Cell Disease
por: Raghupathy, Radha, et al.
Publicado: (2010)

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
por: Haverkos, Bradley, et al.
Publicado: (2023)

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam
por: Koumaki, Vasiliki, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_40p2pem5qs9n17vkfqsreukjtp